Filings Radar

SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.

Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.

LAKELAND FINANCIAL CORP (LKFN)

8-K Earnings release confidence 98% filed 2026-10-26 Item 2.02

This is a clear earnings release disclosing Lakeland Financial Corporation's quarterly and nine-month financial results for the period ended September 30, 2026. The press release reports record third quarter net income of $28.9 million (up 9% year-over-year), diluted EPS of $1.14 (up 11%), and nine-month net income of $83.8 million (up 14%). The disclosure includes comprehensive financial metrics, loan growth of 8%, deposit trends, capital ratios, and management commentary—all hallmarks of a standard quarterly earnings announcement furnished as Exhibit 99.1 under Item 2.02.

View raw filing on EDGAR →

VERIZON COMMUNICATIONS INC (VZ)

8-K Earnings release confidence 99% filed 2026-10-26 Item 2.02

This is a clear earnings release for Q3 2026 results. The Item 2.02 disclosure includes a press release dated October 26, 2026, announcing third-quarter financial results with detailed metrics including revenue ($34.3 billion, up 1.5% YoY), net income ($5.3 billion, up 5.2% YoY), EPS ($1.25, up 6.8% YoY), and Adjusted EBITDA ($13.8 billion, up 8.0% YoY). The filing also includes condensed consolidated financial statements and forward-looking guidance, all hallmarks of a quarterly earnings disclosure material to investors.

View raw filing on EDGAR →

HBT Financial, Inc. (HBT)

8-K Earnings release confidence 97% filed 2026-10-26 Item 2.02

HBT Financial issued a press release on October 26, 2026 announcing third quarter and nine-month financial results for the period ended September 30, 2026, disclosing net income of $31.4 million ($0.86 per diluted share) and a net interest margin of 4.35%.

View raw filing on EDGAR →

111, Inc. (YI)

6-K Governance Other confidence 75% filed 2026-10-26 EX-99.1

The exhibit announces the Special Committee's retention of independent financial and legal advisors (Houlihan Lokey and Kirkland & Ellis) to evaluate a preliminary, non-binding acquisition proposal dated September 16, 2026, and other strategic alternatives. While this governance action (formation and staffing of a special committee to review a potential transaction) is material to investors, it does not constitute a discrete M&A event itself—no definitive offer, agreement, or transaction has been approved or consummated. The disclosure is governance-focused (board committee action and advisor retention) rather than a completed or binding transaction, making `governance_other` the most appropriate classification.

View raw filing on EDGAR →

Ovintiv Inc. (OVV)

8-K M&A activity confidence 99% filed 2026-10-26 Item 1.01

Ovintiv entered into a definitive Arrangement Agreement to acquire Logan Energy Corp. in an all-cash transaction valued at approximately $890 million (C$1.26 billion) including net debt. The acquisition adds approximately 266,000 net acres and 20 MBOE/d of production in the Montney, with expected annual cost synergies of $60 million and is subject to customary closing conditions including shareholder approval, court approval, and competition act approval.

View raw filing on EDGAR →

ArriVent BioPharma, Inc. (AVBP)

8-K Operational Other confidence 75% filed 2026-10-26 Item 8.01

ArriVent disclosed initial Phase 1 clinical trial data for its lead ADC candidate ARR-217, presented at ESMO Congress 2026, showing a 44.8% objective response rate at the 6 mg/kg dose in colorectal cancer patients with a manageable safety profile. The company is advancing ARR-217 to Phase 1b dose optimization with data expected in 2027, representing a material clinical development milestone for the biopharmaceutical pipeline.

View raw filing on EDGAR →

Zhihu Inc. (ZHIHF)

6-K Exec Compensation confidence 95% filed 2026-10-26 EX-99.1

Zhihu Inc. granted 809,802 RSUs to 5 eligible employees on October 16, 2026, pursuant to the Amended and Restated 2022 Share Incentive Plan, with 48-month vesting schedules, performance targets tied to achievement metrics, and clawback provisions for termination or misconduct.

View raw filing on EDGAR →

Elme Communities (ELME)

8-K Delisting risk confidence 97% filed 2026-10-26 Item 3.01

On October 23, 2026, the NYSE notified Elme Communities that it had commenced delisting proceedings and immediately suspended trading due to abnormally low selling price levels under Section 802.01D of the NYSE Listed Company Manual. The company does not intend to appeal and expects its Common Shares will be delisted, with trading anticipated to move to OTC markets.

View raw filing on EDGAR →

ZTO Express (Cayman) Inc. (ZTOEF)

6-K Dividend Distribution confidence 75% filed 2026-10-26 EX-99.3

ZTO Express conducted a share repurchase program between August 12 and October 23, 2026, repurchasing approximately 49.6 million American depositary shares (representing Class A ordinary shares) under a mandate authorized on June 16, 2026. The repurchases were disclosed through three Hong Kong Stock Exchange Next Day Disclosure Returns (Form FF305) documenting 135 separate transactions, representing a material deployment of capital and affecting share count and ownership structure.

View raw filing on EDGAR →

Braemar Hotels & Resorts Inc. (BHR-PD)

8-K Governance Other confidence 85% filed 2026-10-26

The filing discloses the Company's announcement of eight director nominees for election at the 2026 Annual Meeting, including seven new independent directors. This represents a significant board refreshment following the termination of the Company's external advisory relationship with Ashford Inc., with the stated goal of establishing an independent, stockholder-focused board. While this involves multiple director appointments, the central event is the governance restructuring and board slate announcement, which does not fit neatly into the specific `exec_appointment` category (which typically applies to individual officer appointments) but clearly constitutes a material governance matter warranting disclosure under Item 7.01.

View raw filing on EDGAR →

UNITED STATES ANTIMONY CORP (UAMY)

8-K Operational Other confidence 75% filed 2026-10-26 Item 8.01

The company completed and filed a Technical Report Summary on its Nolan Creek Property in Alaska, disclosing mineral resource estimates for antimony-gold deposits and recommendations for future work. This represents a material operational and strategic milestone for the mining exploration company's primary asset.

View raw filing on EDGAR →

Borr Drilling Ltd (BORR)

6-K Operational Other confidence 85% filed 2026-10-26 EX-99.1

This press release discloses a material operational incident involving the loss of the Prospector 5 drilling rig due to a "punch through event" during jacking operations offshore Gabon, resulting in the rig's sinking and five personnel remaining unaccounted for. While the incident involves loss of a material asset and potential loss of life, it does not fit the specific categories of cybersecurity_incident, material_litigation, or other named event types. The disclosure is clearly operational in nature—a catastrophic failure of a key asset during normal operations—making operational_other the most appropriate classification.

View raw filing on EDGAR →

KKR & Co. Inc. (KKR-PD)

8-K Exec appointment confidence 94% filed 2026-10-26 Item 5.02

Brian J. Lee, former Chief Risk Officer of Goldman Sachs, was appointed to KKR & Co. Inc.'s Board of Directors effective October 26, 2026, and will serve on the Audit Committee and Risk Committee. The board size increased to twelve directors.

View raw filing on EDGAR →

Nanobiotix S.A. (NNBXF)

6-K Operational Other confidence 75% filed 2026-10-26 EX-99.1

This press release announces final Phase 1 clinical trial data for JNJ-1900 (NBTXR3) in anti-PD-1-resistant melanoma, presented at ESMO 2026. The disclosure reports efficacy metrics (41.7% ORR, 17.8 months median OS) and safety findings from an ongoing clinical study. While this is a material clinical milestone for a late-stage biotech company's lead candidate, it does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or restatement). It is a material operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and commercial prospects.

View raw filing on EDGAR →

FURY GOLD MINES LTD (FURY)

6-K Operational Other confidence 85% filed 2026-10-26 EX-99.1

This press release announces significant drill results from Fury's Phase 2 exploration program at the Eau Claire Gold Project, including a high-grade intercept of 14.95 g/t gold over 4.25 metres that extends mineralization 60 metres up-dip and validates the geological model. While this is an exploration milestone rather than a discrete operational restructuring or contract event, it represents a material operational/strategic development for an exploration-stage company advancing toward development, supporting conversion of Inferred Resources to Indicated category and a planned pre-feasibility study in 2027.

View raw filing on EDGAR →

AUTOZONE INC (AZO)

8-K Exec departure confidence 95% filed 2026-10-26 Item 5.02

Jamere Jackson, Chief Financial Officer of AutoZone, resigned effective November 25, 2026, to become CFO of FedEx Corporation. The departure of a key financial officer after six years is a material executive change affecting the registrant's leadership and financial oversight.

View raw filing on EDGAR →

ELBIT SYSTEMS LTD (ESLT)

6-K Operational Other confidence 85% filed 2026-10-26 EX-99

This press release announces a $200 million contract award from an Asia-Pacific country for airborne ISTAR and training solutions, including SPECTRO 12 ISR payloads, training systems, and Head-Up Display systems, to be performed over 5 years. While the disclosure is clearly material to investors (a significant contract win affecting revenue and backlog), it does not fit the specific event types for M&A, debt, equity issuance, or other named categories. It is a material operational/commercial milestone—a major contract award—best classified as operational_other.

View raw filing on EDGAR →

InMode Ltd. (INMD)

6-K Governance Other confidence 75% filed 2026-10-26 EX-99.1

This is a shareholder communication from a Special Committee of the Board regarding its ongoing review of strategic alternatives, including acquisition proposals and potential returns of capital. While the letter does not announce a specific transaction or decision, it discloses the Committee's active mandate to evaluate M&A activity and strategic alternatives, which is material governance information. The disclosure addresses the Committee's independence, process, and confidentiality framework—governance matters—rather than announcing a completed event. The reference to "acquisition proposals received by the Company" and "other strategic alternatives" indicates M&A activity is under active consideration, but no specific transaction is disclosed here, making this a governance update rather than a discrete M&A event.

View raw filing on EDGAR →

Eikon Therapeutics, Inc. (EIKN)

8-K Operational Other confidence 75% filed 2026-10-26 Item 8.01

Eikon disclosed updated clinical trial data from the Phase 2 TeLuRide-005 trial of EIK1001 in advanced NSCLC, presented at ESMO Congress on October 26, 2026. The data demonstrated efficacy (63.1% ORR and 89.2% DCR in the pooled population; 72.4% ORR and 100% DCR in the squamous cohort with 12.9-month median duration of response) and a favorable safety profile supporting outpatient administration, representing a material operational milestone supporting advancement toward the Phase 2/3 TeLuRide-008 trial.

View raw filing on EDGAR →

NovaBridge Biosciences (NBP)

6-K Earnings release confidence 75% filed 2026-10-26 EX-99.1

This exhibit is a press release announcing updated Phase 1b clinical trial results for givastomig presented at ESMO 2026, including mature follow-up data (18 months median), dose selection (8 mg/kg), and FDA alignment on Phase 3 strategy. While not a traditional earnings release disclosing financial results, it discloses material clinical and regulatory milestones for the company's lead program that would affect investor assessment of the registrant's value and development trajectory. The announcement emphasizes "registrational-ready" status and represents a significant inflection point in the program's advancement.

View raw filing on EDGAR →

CEMEX SAB DE CV (CXMSF)

6-K Earnings release confidence 95% filed 2026-10-26

The 6-K furnishes three exhibits: a press release dated October 26, 2026 announcing third quarter 2026 results, the Q3 2026 results document, and a presentation regarding Q3 2026 results. This is a discrete earnings announcement for a quarterly period, not a periodic financial report filing. Quarterly earnings releases are material events affecting investor assessment of the registrant's financial performance and condition.

View raw filing on EDGAR →

MakeMyTrip Ltd (MMYT)

6-K Earnings release confidence 98% filed 2026-10-26 EX-99.1

This exhibit is a press release announcing MakeMyTrip Limited's fiscal 2027 second quarter financial results for the period ended September 30, 2026. The document presents comprehensive financial and operating metrics including revenue ($235.2 million), segment performance (air ticketing, hotels, bus ticketing, others), adjusted operating profit, adjusted EBITDA, and diluted earnings per share ($0.02), along with year-over-year comparisons and constant-currency analysis. This is a discrete earnings announcement, not a periodic financial report filing itself.

View raw filing on EDGAR →

Phathom Pharmaceuticals, Inc. (PHAT)

8-K Material Litigation confidence 92% filed 2026-10-26 Item 8.01

Phathom disclosed litigation brought by BDR Pharmaceuticals challenging the FDA's June 6, 2025 decision granting Phathom's Citizen Petition regarding 10 years of NCE exclusivity for VOQUEZNA through May 3, 2032. The FDA has established a public docket to solicit comments on this matter, and a second ANDA filer (Saba Ilac) has indicated intent to consolidate its case with BDR's. This litigation directly threatens Phathom's regulatory exclusivity period for its lead product, making it material to investors assessing the company's competitive position and revenue protection.

View raw filing on EDGAR →

Oaktree Acquisition Corp. III Life Sciences (OACCW)

8-K Dilutive issuance confidence 85% filed 2026-10-26 Item 3.02

Oaktree Acquisition Corp. III Life Sciences issued 4,798,758 Class A ordinary shares to the Sponsor upon conversion of Class B shares, with the shares explicitly stated as unregistered under the Securities Act of 1933 and issued in reliance on Section 3(a)(9) exemption. This unregistered equity issuance increases the Sponsor's Class A holdings and dilutes existing shareholders.

View raw filing on EDGAR →

Oaktree Acquisition Corp. III Life Sciences (OACCW)

8-K Shareholder vote confidence 95% filed 2026-10-26 Item 5.07

Shareholders voted on October 23, 2026 to approve an Extension Amendment Proposal extending the business combination termination date from October 25, 2026 to November 25, 2026, with provisions for further monthly extensions up to May 25, 2027. The proposal passed with 17,956,072 votes in favor and 802,517 against, with 11.3 million Public Shares redeemed for approximately $122.4 million.

View raw filing on EDGAR →

SK hynix Inc.

6-K Other material confidence 72% filed 2026-10-26

SK hynix issued a clarification regarding media reports of a potential special dividend of approximately Won 16 trillion funded by gains from a Kioxia stake sale. While the company states no matters have been determined, the disclosure addresses a material capital allocation decision (special dividend) and references a significant asset disposition (Kioxia stake sale). The event does not fit neatly into a single category—it involves both a potential dividend distribution and an asset sale—and the company's statement that shareholder return measures will be announced at the Q3 earnings call suggests an imminent material announcement. This is material to investors assessing capital allocation and shareholder returns.

View raw filing on EDGAR →

Climb Bio, Inc. (CLYM)

8-K Operational Other confidence 85% filed 2026-10-26 Item 8.01

Climb Bio announced initial Phase 2 clinical trial data for budoprutug in primary membranous nephropathy (pMN) and minimal change disease (MCD), presented at ASN Kidney Week 2026. The data demonstrate 70% mean PLA2R antibody reduction, 38% immunologic remission at 200 mg, generally good tolerability, and no serious adverse events, supporting dose escalation and representing a material clinical milestone for the company's lead program.

View raw filing on EDGAR →

MakeMyTrip Ltd (MMYT)

6-K Earnings release confidence 98% filed 2026-10-26 EX-99.1

This is an earnings press release announcing MakeMyTrip's unaudited financial and operating results for fiscal Q2 ended September 30, 2026. The exhibit explicitly states "EARNINGS PRESS RELEASE" and discloses key financial metrics including Gross Bookings ($2,724.7M, up 20.9% YoY), Revenue ($235.2M, up 11.2%), Adjusted Margin by segment, and Adjusted Operating Profit ($46.2M). The disclosure includes management commentary from the CEO and is material to investors assessing the registrant's financial performance and operational trends.

View raw filing on EDGAR →

Sanofi (SNYNF)

6-K Operational Other confidence 85% filed 2026-10-26 EX-99.1

This press release announces Sanofi's groundbreaking of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, with full production planned for 2032. The disclosure describes a significant capital investment in manufacturing infrastructure and capacity expansion for a core product line (insulin), which is an operational and strategic business event. While the facility represents a material long-term commitment to supply chain resilience and production capacity, it does not fit the specific event types for M&A activity, workforce reduction, or other discrete operational milestones; it is best classified as a material operational/strategic initiative.

View raw filing on EDGAR →

HDFC BANK LTD (HDB)

6-K Exec Compensation confidence 95% filed 2026-10-26 EX-99

The disclosure announces a grant of 13,02,379 equity stock options by the Governance, Nomination and Remuneration Committee under the Employees' Stock Option Scheme (ESOS) – Plan H-2024. This is a compensatory arrangement for employees involving equity grants with specified vesting schedules and exercise terms, which falls squarely within exec_compensation. The materiality is high given the large number of options granted and the regulatory framework (SEBI regulations) governing the scheme.

View raw filing on EDGAR →

RANGE RESOURCES CORP (RRC)

8-K M&A activity confidence 99% filed 2026-10-26 Item 1.01

Range Resources entered into a definitive Agreement and Plan of Merger with EQT Corporation on October 25, 2026, whereby EQT will acquire Range in an all-stock transaction at an exchange ratio of 0.987 shares of EQT common stock per Range share, creating a combined company with pro forma enterprise value exceeding $50 billion and subject to customary closing conditions including shareholder and regulatory approvals.

View raw filing on EDGAR →

Stratum Holdings Corp. (LRHC)

8-K Dilutive issuance confidence 95% filed 2026-10-26

The filing discloses an unregistered sale of equity securities under Item 3.02. On October 26, 2026, Stratum Holdings Corp. issued 200 shares of Series E Convertible Preferred Stock to an institutional investor for $200,000 gross proceeds, pursuant to Rule 506(b) under Regulation D. This is a private placement of convertible preferred stock, which is a dilutive issuance typical of small-cap companies raising capital.

View raw filing on EDGAR →

Game Your Game Inc.

8-K Dilutive issuance confidence 78% filed 2026-10-26 Item 1.01

The Company amended warrants to purchase 1.5 million shares, reducing the exercise price to $1.00 per share and obtaining a waiver of trigger provisions in related Securities Purchase Agreements. This amendment materially increases the dilutive potential of the warrants and represents a significant modification to the Company's capital structure through the re-pricing of equity instruments downward.

View raw filing on EDGAR →

Game Your Game Inc.

8-K Exec appointment confidence 85% filed 2026-10-26 Item 5.02

The Company appointed Wendy Loundermon as Chief Financial Officer effective October 16, 2026, with a comprehensive employment agreement including base salary of $200,000, a signing bonus of $25,000, stock options for 200,000 shares, and acquisition bonus provisions.

View raw filing on EDGAR →

Amanat Acquisition Corp. (AMAN)

8-K M&A activity confidence 97% filed 2026-10-26 Item 1.01

Amanat Acquisition Corp. entered into a definitive Business Combination Agreement with Corxel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, with an implied Corxel equity value of $200 million and approximately $377 million in gross proceeds. The transaction includes a $300 million PIPE financing and is expected to close in H1 2027, subject to customary conditions including shareholder approval and HSR clearance.

View raw filing on EDGAR →

Amanat Acquisition Corp. (AMAN)

8-K Dilutive issuance confidence 95% filed 2026-10-26 Item 3.02

Amanat disclosed unregistered sales of approximately $300 million in equity securities to institutional investors as part of the PIPE financing, including issuance of New Corxel Common Stock and PIPE Pre-Funded Warrants relying on Section 4(a)(2) exemption.

View raw filing on EDGAR →

EQT Corp (EQT)

8-K M&A activity confidence 99% filed 2026-10-26 Item 1.01

EQT Corporation entered into a definitive Agreement and Plan of Merger with Range Resources Corporation on October 25, 2026, under which EQT will acquire Range in an all-stock transaction with an exchange ratio of 0.987 EQT shares per Range share. The transaction creates a combined company with pro forma enterprise value exceeding $50 billion, contemplates substantial synergies ($325M base, pathway to $600M+), and is expected to close in Q1 2027 subject to shareholder approval and regulatory clearance.

View raw filing on EDGAR →

CCH Holdings Ltd (CCHH)

6-K Governance Other confidence 88% filed 2026-10-26 EX-99.1

CCH Holdings Ltd is seeking shareholder approval for a redomiciliation from the Cayman Islands to the British Virgin Islands, a change of company name to Foodverse Holding Limited, and adoption of amended memorandum and articles of association. The extraordinary general meeting is scheduled for November 3, 2026, and requires a special resolution (two-thirds vote) for approval.

View raw filing on EDGAR →

Marti Technologies, Inc. (MRT)

6-K Material Litigation confidence 92% filed 2026-10-26

The 6-K discloses a favorable appellate court decision in an unfair competition lawsuit brought by Turkish drivers' and automobile trade associations against Marti's ride-sharing platform. The Istanbul Regional Court of Appeals unanimously dismissed the plaintiffs' claims and rejected their requests for interim measures to block access to services. This is a material litigation outcome that removes significant regulatory and operational risk to the company's core ride-sharing business in Turkey.

View raw filing on EDGAR →

Jumia Technologies AG (JMIA)

6-K Exec appointment confidence 95% filed 2026-10-26

The Supervisory Board appointed three individuals—Pedro Fangueiro, Renaud Glenisson, and Hesham El Gabry—as members of the Management Board effective October 19, 2026. Additionally, Francis Dufay was appointed as Chair of the Management Board. These are executive appointments to senior leadership roles at the registrant, expanding the Management Board from two to five members and establishing new governance structure.

View raw filing on EDGAR →

Getty Images Holdings, Inc. (GETY)

8-K Bankruptcy Filing confidence 98% filed 2026-10-26 Item 1.03

Getty Images Holdings, Inc. filed voluntary Chapter 11 bankruptcy petitions on October 21, 2026, in the U.S. Bankruptcy Court for the District of Delaware. The company secured debtor-in-possession (DIP) financing to support operations during the bankruptcy process.

View raw filing on EDGAR →

Can-Fite BioPharma Ltd. (CANF)

6-K Operational Other confidence 75% filed 2026-10-26 EX-99.1

This press release announces final positive Phase IIa clinical trial data for namodenoson in pancreatic cancer presented at ESMO 2026, including achievement of the primary safety endpoint and exploratory survival findings. While the disclosure concerns clinical development progress—a material operational milestone for a biotech company—it does not fit the specific event types of earnings_release, ma_activity, material_litigation, or other named categories. The data presentation represents a significant clinical advancement that would affect a reasonable investor's assessment of the company's pipeline and development trajectory, warranting classification as operational_other.

View raw filing on EDGAR →

HyOrc Corp (HYOR)

8-K M&A activity confidence 75% filed 2026-10-26

The filing discloses termination of a material definitive agreement dated March 23, 2026 relating to a proposed Bulgarian waste-to-methanol project under Item 1.02. Although the Company disputes the validity of the termination and maintains contractual conditions were not met, the notice from OnEnergy purporting to discontinue the Company's participation in this joint project constitutes a material event affecting the registrant's strategic initiatives and potential business opportunities.

View raw filing on EDGAR →

Artificial Intelligence Technology Solutions Inc. (AITX)

8-K Operational Other confidence 72% filed 2026-10-26

The filing discloses four internal operating milestones toward breakeven, including a workforce reduction of approximately 24 positions (7 in August, 17 in October 2026) and cost-reduction initiatives totaling over $350,000 monthly. While the milestones themselves are non-GAAP internal measures, the underlying operational restructuring—workforce reductions, cost cuts, and strategic repositioning—constitutes a material operational event. The company explicitly references "substantial doubt about the Company's ability to continue as a going concern," but the primary disclosed action is operational restructuring rather than a going-concern disclosure per se.

View raw filing on EDGAR →

Robot Consulting Co., Ltd. (LAWR)

6-K Delisting risk confidence 98% filed 2026-10-26 EX-99.1

Robot Consulting announced receipt of a Nasdaq delisting determination from the Listing Qualifications Department pursuant to Nasdaq Listing Rules 5101 and IM-5101-4, based on concerns regarding historical trading activity and potential for third-party manipulation of the Company's securities. Although the Company has appealed and the delisting suspension is stayed pending the Panel's review, this is a material disclosure of delisting risk that would significantly affect a reasonable investor's assessment of the registrant's continued listing status and market access.

View raw filing on EDGAR →

NEWS CORP (NWSLL)

8-K Dividend Distribution confidence 92% filed 2026-10-26 Item 8.01

News Corporation is disclosing ongoing execution of its $1 billion share repurchase program authorized July 15, 2025, with daily buy-back notifications to the ASX showing approximately $550.2 million in cumulative purchases to date across Class A and Class B common stock. Share repurchases constitute a return of capital to shareholders and are classified as dividend_distribution events under the taxonomy, distinct from operational or financial restructuring.

View raw filing on EDGAR →

Easterly Government Properties, Inc. (DEA)

8-K Earnings release confidence 98% filed 2026-10-26 Item 2.02

This is a clear earnings release for Q3 2026 ended September 30, 2026. The Item 2.02 disclosure explicitly states "we issued a press release announcing our results of operations for the third quarter ended September 30, 2026," with the press release attached as Exhibit 99.1 reporting net income of $5.7 million ($0.12 per share), Core FFO of $38.0 million ($0.78 per share), and updated 2026-2027 guidance. This is a standard quarterly earnings announcement material to investors.

View raw filing on EDGAR →

Vertiv Holdings Co (VRT)

8-K M&A activity confidence 95% filed 2026-10-26 Item 7.01

Vertiv announced the completion of its acquisition of King Environmental Services Ltd., a Europe-based provider of fluid management and commissioning services. The press release explicitly states "Vertiv Holdings Co. (NYSE: VRT)...today announced it has completed its acquisition of King Environmental Services Ltd. (KES)" and describes the strategic rationale for the transaction, including expansion into EMEA and building on prior thermal management acquisitions. This is a material acquisition completion that would affect investor assessment of the company's growth strategy and capital deployment.

View raw filing on EDGAR →

Acumen Pharmaceuticals, Inc. (ABOS)

8-K Earnings release confidence 94% filed 2026-10-26 Item 2.02

Acumen Pharmaceuticals disclosed third quarter 2026 financial results on October 26, 2026, reporting R&D expenses of $21.1 million, G&A expenses of $4.7 million, net loss of $25.4 million, and cash position of $78.6 million as of September 30, 2026, along with business highlights regarding the ALTITUDE-AD Phase 2 trial and EBD program milestones.

View raw filing on EDGAR →

HUTCHMED (China) Ltd (HMDCF)

6-K Earnings release confidence 92% filed 2026-10-26 EX-99.1

HUTCHMED announced positive Phase III clinical trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in MET-driven EGFR-mutated NSCLC, demonstrating statistically significant improvements in progression-free survival (45% risk reduction, HR 0.55, p<0.001) and overall survival (32% risk reduction, HR 0.68, p=0.010), with median OS extended by 4.9 months. Results were simultaneously published in The New England Journal of Medicine and presented at ESMO Congress 2026.

View raw filing on EDGAR →